Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38,147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First and Second-line Treatments in Metastatic Renal Cell Carcinoma.
Barragan-Carrillo R, Saad E, Saliby RM, Sun M, Albiges L, Bex A, Heng D, Mejean A, Motzer RJ, Plimack ER, Powles T, Rini BI, Zhang T, Choueiri TK. Barragan-Carrillo R, et al. Among authors: zhang t. Eur Urol. 2024 Nov 5:S0302-2838(24)02681-2. doi: 10.1016/j.eururo.2024.10.019. Online ahead of print. Eur Urol. 2024. PMID: 39505582 Review.
First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study.
El Zarif T, Semaan K, Xie W, Eid M, Zarba M, Issa W, Zhang T, Nguyen CB, Alva A, Fahey CC, Beckermann KE, Karam JA, Campbell MT, Procopio G, Stellato M, Buti S, Zemankova A, Melichar B, Massari F, Mollica V, Venugopal B, Ebrahimi H, de Velasco G, Gurney HP, De Giorgi U, Parikh O, Winquist E, Master V, Garcia AR, Cutuli HJ, Ferguson TR, Gross-Goupil M, Baca SC, Pal SK, Braun DA, McKay RR, Heng DYC, Choueiri TK. El Zarif T, et al. Among authors: zhang t. Eur Urol. 2024 Aug 14:S0302-2838(24)02499-0. doi: 10.1016/j.eururo.2024.07.016. Online ahead of print. Eur Urol. 2024. PMID: 39147674
Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma.
Shayeb AM, McManus HD, Urman D, Jani C, Zhang T, Dizman N, Meza L, Sivakumar A, Gan CL, Barata P, Bilen MA, Gao X, Heng D, Pal S, Narra R, Kilari D, Kaymakcalan MD, McGregor B, Choueiri TK, McKay RR. Shayeb AM, et al. Among authors: zhang t. Clin Genitourin Cancer. 2023 Feb;21(1):55-62. doi: 10.1016/j.clgc.2022.10.013. Epub 2022 Nov 3. Clin Genitourin Cancer. 2023. PMID: 36411184
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. Among authors: zhang p. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.
Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.
Tucker MD, Brown LC, Chen YW, Kao C, Hirshman N, Kinsey EN, Ancell KK, Beckermann KE, Davis NB, McAlister R, Schaffer K, Armstrong AJ, Harrison MR, George DJ, Rathmell WK, Rini BI, Zhang T. Tucker MD, et al. Among authors: zhang t. Biomark Res. 2021 Nov 3;9(1):80. doi: 10.1186/s40364-021-00334-4. Biomark Res. 2021. PMID: 34732251 Free PMC article.
The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma.
Chen YW, Tucker MD, Brown LC, Yasin HA, Ancell KK, Armstrong AJ, Beckermann KE, Davis NB, Harrison MR, Kaiser EG, McAlister RK, Schaffer KR, Wallace DE, George DJ, Rathmell WK, Rini BI, Zhang T. Chen YW, et al. Among authors: zhang t. Cancers (Basel). 2022 Aug 7;14(15):3830. doi: 10.3390/cancers14153830. Cancers (Basel). 2022. PMID: 35954493 Free PMC article.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. Among authors: zhang t. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma.
Gulati S, Barata PC, Elliott A, Bilen MA, Burgess EF, Choueiri TK, Darabi S, Dawson NA, Gartrell BA, Hammers HJ, Heath EI, Magee D, Rao A, Ryan CJ, Twardowski P, Wei S, Brugarolas J, Zhang T, Zibelman MR, Nabhan C, McKay RR. Gulati S, et al. Among authors: zhang t. J Clin Invest. 2024 May 30;134(14):e176230. doi: 10.1172/JCI176230. J Clin Invest. 2024. PMID: 39007269 Free PMC article.
38,147 results
You have reached the last available page of results. Please see the User Guide for more information.